TheEdgeResearch
Home / Stocks / BBZA.DE

BB Biotech AG (BBZA.DE)

XETRA Healthcare Biotechnology
$57.40 ▲ +0.17%
Market Cap
$3.17B
Sector
Healthcare
Industry
Biotechnology
Beta
0.62
52-Wk Range
33.4-57.4
CEO
Daniel Koller
Country
CH
Currency
EUR

BB Biotech AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Kusnacht, CH. The stock last traded at $57.40, up 0.17% on the session, giving a market capitalisation of $3.17B. Its beta of 0.62 implies it has historically moved less than the broad market.

Company profile
Exchange
Deutsche Börse
Employees
10
IPO date
2020-06-29
Headquarters
Kusnacht, CH
About BB Biotech AG

BB Biotech AG functions as an equity investment vehicle, managed by Bellevue Asset Management AG. Its investment mandate extends to publicly traded companies across the globe, with a particular focus on firms engaged in modern biotechnology for medications and diagnostic tools. The construction of its portfolio is driven by a rigorous fundamental analysis. This Swiss-domiciled entity was established on November 9, 1993.

Comparable companies

BB Biotech AG is most often compared with the following Healthcare names:

AFX.DEBNN.DEBZ7A.FHPHA.DENVV1.F
More research on BBZA.DE
BBZA.DE technical analysis BBZA.DE TheEdge Score Compare against peers
Open full interactive analysis & DCF →